WO2026105061 - ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/105061
Publication Date
21.05.2026
International Application No.
PCT/IB2025/061667
International Filing Date
14.11.2025
Title **
[English]
ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT SE LIANT À CDCP1 ET LEURS UTILISATIONS
Applicants **
PHEON THERAPEUTICS LTD
Inventors
PROCOPIOU, George
JACKSON, Paul
Priority Data
63/721,161
15.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 30142 | |
| EPO | Filing, Examination, Granting | 1438673 | |
| Japan | Filing, Examination, Granting | 9954 | |
| South Korea | Filing, Examination, Granting | 62212 | |
| USA | Filing, Examination, Granting | 260290 |
Total:
1,801,271
Contact Us
Abstract[English]
The present disclosure provides compounds and antibody-drug conjugates and methods of use thereof, including methods for treating cancer.[French]
La présente divulgation concerne des composés et des conjugués anticorps-médicament ainsi que des méthodes d'utilisation de ceux-ci, y compris des méthodes de traitement du cancer.